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Abstract
Introduction: Infection with HIV subtype A has been associated with poorer neurocognitive outcomes compared to HIV sub-
type D in Ugandan children not eligible for antiretroviral therapy (ART). In this study, we sought to determine whether sub-
type-specific differences are also observed among children receiving ART.
Materials and Methods: Children were recruited from a clinical trial in which they were randomized to receive either lopina-
vir (LPV)- or non-nucleoside reverse transcriptase inhibitor (NNRTI)- based ART (NCT00978068). Age at initiation of ART ran-
ged from six months to six years. HIV subtype was determined by PCR amplification and population sequencing of the pol
region derived from peripheral blood mononuclear cell DNA, followed by application of the REGA and Recombinant Identifica-
tion Programme algorithms. General cognition was assessed using the Kaufman Assessment Battery for Children (Second Edi-
tion), attention using the Test of Variables of Attention, and motor skills using the Bruininks-Oseretsky Test of Motor
Proficiency (Second Edition). Home environment was assessed using the Home Observation for the Measurement of the Envi-
ronment (HOME). Age-adjusted test z-scores were entered into a regression model that adjusted for sex, socio-economic sta-
tus score, HOME score, years of schooling, and ART treatment type.
Results: One hundred and five children were tested; median (interquartile range) age was 7.05 years (6.30 to 8.44), CD4
count was 867.7 cells/mm3 (416.0 to 1203.5), and duration on ART was 4.03 years (3.55 to 4.23). Seventy-eight children had
HIV subtype A and 27 had subtype D; the groups had comparable home and socio-economic status, except that there were
more males among children infected with subtype A than D (64.7% vs. 35.3%, p = 0.02). There were no differences between
the subtypes in general cognition (estimated mean difference: 0.20; 95% CI: 0.11 to 0.50); p = 0.21), attention (0.18, 95%
CI: 0.60 to 0.24, p = 0.41) and motor skills (1.60, 95% CI: 0.84 to 4.04, p = 0.20).
Conclusions: Our results imply that ART may diminish the neurocognitive disadvantage seen in treatment-na€ıve HIV-infected
children with subtype A.
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1 | INTRODUCTION
Access to antiretroviral therapy (ART) in low and middle-income
countries has increased over the years and contributed to
improved health outcomes in HIV-infected children including
neurocognitive outcomes [1,2]. However, neurocognitive defi-
cits are still observed in children receiving ART, underscoring
the need to optimize treatment [3,4]. Studies evaluating neu-
rocognitive outcomes in HIV-infected children have identified
key factors associated with poor outcome including high viral
load, low CD4 counts, and high levels of soluble P-selectin and
fibrinogen [5–7]. The time between sample collection and neu-
rocognitive testing varies in these studies [8,9].
Data describing the influence of HIV-subtype on neurocog-
nitive function are conflicting. Our group previously reported
that HIV subtype A was associated with poorer neurocogni-
tive outcomes than subtype D in ART na€ıve children [8]. The
poorer neurocognitive outcomes in children with subtype A
was speculated to be a consequence of increased CCR5 affin-
ity associated with HIV subtype A, that could in turn lead to
increased ability to infect macrophages and enter the central
nervous system (CNS) [8]. Our study above in children con-
trasted with observations by Sacktor et al. in HIV-infected
adults with advanced immune suppression where subtype D
and not A was associated with poorer neurocognitive out-
comes [10]. Another study by Sacktor el al. found no
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differences by subtype in adults with moderate immune
suppression [11].
In addition to diseases like HIV, malaria and meningitis,
environmental variables like child and parental education,
socio-economic status of the family, quality of the home envi-
ronment and the child’s nutritional status affect cognition in
children in sub-Saharan Africa [12–14]. These variables need
to be accounted for when studying cognitive function in chil-
dren with HIV or other CNS infections.
Adverse drug reactions, e.g. toxicities are one of the main
factors influencing ART regimen choice and adherence [15,16].
Subtype-specific differences in neurocognitive outcomes could
also have implications for clinical management of children
infected with subtype A, requiring administration of drugs
with better CNS penetration to mitigate the virus’ effect on
the brain. Current WHO guidelines recommend that all HIV-
infected children are initiated on ART regardless of the dis-
ease stage, promoting universal ART coverage [17]. To better
inform ART regimen decision-making, we investigated whether
variations in neurocognitive outcomes associated with HIV
subtype are also observed in HIV-infected children on ART. In
this study, we compared neurocognitive outcomes between
HIV subtype A-infected and HIV subtype D-infected children
on suppressive ART.
2 | METHODS
The study was conducted between December 2013 and
May 2015 in Tororo district, eastern Uganda. Participants
were recruited from a cohort of children who had partici-
pated in the PROMOTE-Paediatrics trial conducted from
September 2009 to July 2011 which recruited children
aged two months to five years not yet on ART or receiving
the standard first-line ART as per national guidelines at that
time [18]. Participants in the PROMOTE-Paediatrics trial
were randomized to receive either protease inhibitors (PI)
(lopinavir-ritonavir plus two nucleoside reverse transcriptase
inhibitors (NRTIs)) or non-nucleoside reverse transcriptase
inhibitors (NNRTI) nevirapine (for children less than three
years of age) or efavirenz (for children ≥3 years of age) –
plus two NRTIs. Lamivudine and zidovudine were the NRTIs
used, with stavudine or abacavir replacing zidovudine in chil-
dren who had anaemia. Majority of the children (71%) were
HAART naive at the start of the study [19]. Children who
were already receiving ART were randomly assigned to
continue their current regimen or to switch to lopinavir-
ritonavir while continuing the same NRTIs. Children were
followed up for six months to two years to record malaria
incidence [18]. At the conclusion of the study, the majority
of children randomized to LPV/r were changed to NNRTI-
based treatment.
This study began two years after the parent trial had closed
[18]. Inclusion criteria for this study included: a) age 5 years
to 12 years, b) no history of malnutrition or other CNS infec-
tion as reported by the mother, c) currently or formerly
enrolled in the PROMOTE-Paediatrics trial. Children were
traced and those meeting eligibility criteria were assessed for
general cognition, working memory (sequential processing),
visual-spatial processing (simultaneous processing), Learning,
and planning (reasoning) using the Kaufman Assessment
Battery for Children (Second Edition) (KABC-II) [20]. Attention
was assessed using the D’ Prime score of the Test of Vari-
ables of Attention (TOVA) [21], and motor skills using the
Total Score of the Bruininks-Oseretsky Test of Motor Profi-
ciency (Second Edition) (BOT-2) [22]. The battery of tests
used in this study had previously been used in HIV-infected
Ugandan children [5,8,23]. The KABC-II and TOVA have been
validated for use in Uganda and in similar settings where they
demonstrated stable construct validity and were sensitive to
education exposure and health indicators [24–26].
Home environment was assessed using the Home Observa-
tion for the Measurement of the Environment (HOME) [27]
and nutrition was assessed using height- and weight-for-age z
scores (Epi Info version 3.5.3; Centers for Disease Control
and Prevention). Socio-economic status was assessed using a
checklist of material possessions, housing quality, cooking
resources and water accessibility [12]. HIV subtype and
recombinant status were determined by PCR amplification
and population sequencing of the pol region [28] derived from
peripheral blood mononuclear cell (PBMC) DNA, followed by
application of the REGA subtyping tool v2.0 and Recombinant
Identification Programme algorithm [29,30]. Viral load and
CD4 data were obtained from the PROMOTE-Paediatrics trial
data.
Written informed consent was provided by the parents and
caregivers of the children prior to enrolment. Assent was also
provided by children aged seven years and older. The study
was approved by the Research and Ethics Committee at Mak-
erere University School of Medicine and the Uganda National
Council for Science and Technology.
2.1 | Statistical analyses
The primary outcomes were general cognition, attention and
motor skills. Their distributions were evaluated, and no outly-
ing values were detected. Age adjusted z-scores (with a mean
of 0 and standard deviation of 1) were derived from age-
matched community controls (N = 210) from the same region
for general cognition, working memory, visual spatial process-
ing, planning and attention as previously described [31]. These
controls were participating in another study that administered
the KABC-II and TOVA. Z scores less than or equal to 1
were categorized as mild neurocognitive impairment. Age-
adjusted standard scores based on US norms, with a mean of
50 and standard deviation of 10, were used for motor skills
since there were no appropriate controls assessed with the
BOT-2. Chi-square and T tests were used to compare baseline
socio-demographic and clinical measures between the groups.
Test scores were compared between the HIV subtypes using
analysis of covariance (ANCOVA) while controlling for sex,
socio-economic status score, HOME score, years of schooling,
and ART regimen. Weight-for age z-score, viral load and CD4
were not included to avoid potential co-linearity with HIV sub-
type. Least square (LS) means and their standard errors (SE)
were derived from the ANCOVA and compared by subtype
using t-tests. Chi-square or Fisher’s exact tests were used to
compare the rates of mild neurocognitive impairment between
the groups.
In our previous study of cognition by subtype in ART na€ıve
children [8], 37 children infected with subtype A had a mean
sequential processing score of 29.11 (SD=5.33) while the 16
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children infected with subtype D had a mean (SD) of 31.81
(6.36). These differences corresponded to an effect size of
Cohen’s d = 0.48. In this study, the available sample sizes of
78 and 27 in the subtype groups allowed detection of differ-
ences corresponding to d = 0.63 or greater as statistically sig-
nificant in two-tailed tests with power of 0.80 or greater and
0.05 level of significance. In addition to statistical significance
testing, we estimated the magnitude of the effect sizes in this
study. The adjusted effect sizes were computed as the differ-
ence between LS means divided by the square root of the
mean squared error in the ANCOVA model.
3 | RESULTS
3.1 | Demographic characteristics by HIV Subtype
Of the 163 children who completed the parent trial, 162 were
traced and screened for enrolment; 158 met eligibility criteria
and were enrolled into this study. Viral subtype could not be
determined for 49 children due to sample unavailability, and
four children had subtype C or AD infection. We therefore
analysed data for 105 children; 78 had subtype A and 27 had
subtype D with a higher proportion of males seen with D ver-
sus A (69.2% vs. 42.3%, p = 0.02). The mean age (SD) was
7.38 (1.37) with a range of 5.01 to 10.21 (Table 1). There
were no differences by subtype with respect to age, child’s
education, nutritional status, quality of the home environment,
socio-economic status, number of malaria episodes during the
parent trial, latest viral load, latest CD4 count, or duration of
ART (median 4.16 years). There was no statistical difference
in the proportion of children who received PIs versus NNRTIs
between children infected with subtype A and D.
3.2 | Neurocognitive outcomes by subtype
No differences in neurocognitive outcome were observed
between children infected with subtypes A versus D for both
primary and secondary outcomes after controlling for con-
founding variables (Table 2). Though it was not statistically sig-
nificant, only the difference in visual-spatial processing
between subtypes A versus D corresponded to a practically
meaningful effect size of 0.42. The frequency of mild neu-
rocognitive impairment was not different between the groups
(Table 3). 33.3% of the children had mild cognitive impairment
in at least one of the areas tested (except motor skills for
which no appropriate controls were present). In addition,
there were no differences in neurocognitive outcomes
between children receiving PIs versus NNRTIs. Years in
school, nutritional status (WAZ and HAZ scores), HOME score
and SES score were associated with a number of neurocogni-
tive outcomes (Table 4). There was a sex difference in test
performance with males performing better than females on
tests for motor skills and visual-spatial processing. Viral load
and absolute CD4 count were not significantly correlated with
any of the outcomes.
Table 1. Socio-demographic characteristics and baseline labora-
tory measures of the study participants
Variable
Subtype A
(N = 78)
Subtype
D (N = 27) p
Age (years) 7.32 (1.42) 7.57 (1.21) 0.41
Sex (male) N (%) 33 (42.31) 18 (69.23) 0.02
Years in school 2.17 (1.33) 2.11 (0.75) 0.84
Weight for age
Z score
1.07 (1.05) 1.14 (1.10) 0.75
Height for age
Z score
0.76 (1.17) 1.20 (0.94) 0.09
HOME score 0.06 (0.99) 0.41 (0.99) 0.12
SES score 9.08 (3.60) 8.63 (3.28) 0.57
Treatment arm,
(PI) N (%)
43 (55.1) 12 (44.4) 0.34
Treatment duration
(years)
4.05 (0.51) 3.98 (0.52) 0.53
Number of malaria
episodes
3.82 (5.68) 4.04 (4.48) 0.86
Viral load
≤400, N (%) 67 (85.9%) 23 (85.2%) 0.99a
>400, N (%) 11 (14.1%) 4 (14.8%)
CD4 count 1026.09 (445.30) 1057.78 (433.84) 0.75
All figures are Mean (SD) unless otherwise stated. HOME, Home
Observation for the Measurement of the Environment; PI, protease
inhibitors; SES, socio-economic status score.
aFisher’s exact test.
Table 2. Comparison of age-adjusted z-scores between subtypes A and D, adjusted for sex, socio-economic status, quality of the
home environment, years of schooling, and trial arm
Variable
Subtype A
LS mean (SE)
Subtype D
LS mean (SE) Mean difference (95% confidence interval) p Adj. effect size
Overall cognition 0.05 (0.07) 0.14 (0.13) 0.20 (0.11 to 0.50) 0.20 0.31
Attention 0.08 (0.10) 0.25 (0.18) 0.18 (0.60 to 0.24) 0.41 0.20
Motor skillsa 32.66 (0.60) 31.06 (1.04) 1.60 (0.84 to 4.04) 0.20 0.31
Working memory 0.18 (0.08) 0.24 (0.13) 0.06 (0.26 to 0.37) 0.73 0.08
Visual-spatial processing 0.06 (0.07) 0.19 (0.12) 0.25 (0.03 to 0.54) 0.08 0.42
Learning 0.20 (0.14) 0.18 (0.25) 0.38 (0.19 to 0.95) 0.19 0.32
Reasoning 0.13 (0.10) 0.04 (0.18) 0.10 (0.32 to 0.51) 0.65 0.11
aStandard scores were used since z-scores were not available for this domain.
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4 | DISCUSSION
This study compared neurocognitive outcomes between HIV
subtype A-infected and subtype D-infected Ugandan children
on ART. We did not find a difference in neurocognitive out-
comes by subtype in this cohort of ART-treated children, in
contrast to our prior study of ART-na€ıve children [8]. We
speculate that suppression of viral replication by ART relieves
neurocognitive deficits in both groups of children to near nor-
mal levels, effectively eliminating subtype-specific differences.
We had previously observed that high HIV viral load was
associated with neurocognitive impairment in Ugandan chil-
dren who were not on ART [5]. In that same cohort, children
infected with subtype A who had poorer neurocognitive out-
comes also had higher HIV viral load than subtype D-infected
children [8]. In this study, there was no difference in viral load
between children infected with subtype A versus subtype D.
This current study adds to mounting evidence about the
benefits of ART on neurocognitive outcomes. Brahmbhatt
et al. showed that Ugandan children aged zero to six years
who had been on ART for 24 to 60 months had decreased
impairments in fine motor, receptive language, expressive lan-
guage and in overall neurodevelopment compared to those
who had been on ART for <12 months [32]. A later study by
Brahmbhatt et al. among children aged 7 to 14 years showed
that longer duration on ART significantly reduced the risk of
impairment in working memory assessed using the KABC-II
[23]. However, they observed higher rates of disability mea-
sured by the KABC-II in Ugandan HIV-infected children who
were receiving ART compared to controls [23]. We similarly
observed in this study that despite being on ART, 33.3% of
the children had mild cognitive impairment in the KABC-II and
TOVA. Neurocognitive impairment in HIV-infected children
who are on ART highlights the need for comprehensive ser-
vices for school going HIV-infected children that may include
educational, neurocognitive and behavioural interventions
[23,33].
The present study’s correlations between the socio-demo-
graphic variables and neurocognitive outcome are consistent
with earlier studies in Uganda and elsewhere in sub-Saharan
Africa [12,14,34]. Bangirana et al. observed that education
level of the child was associated with more neurocognitive
abilities than other socio-demographic factors as was
observed in the present study [12]. Similarly, nutritional fac-
tors (WAZ and HAZ) and the HOME score correlated with a
number of abilities in this study as was observed in the earlier
study [12]. These findings have implications for interventions
to improve neurocognitive outcome in HIV-infected children.
For example, Boivin et al. provided an intervention that
enhanced the quality of the mother-child interaction that
resulted in improved cognitive scores in Ugandan HIV-infected
children [35].
This study has several limitations. There was a time lag of
four years in evaluating the children after randomization dur-
ing which time, number of malaria episodes and viral load that
could affect neurocognitive outcome were not measured.
Without pretreatment data, it is impossible to know the
extent of subtype differences in the cohort, as well as to
determine changes in neurocognitive outcomes after treat-
ment and whether these differed by subtype. In addition, viral
load levels and CD4 counts were measured during the PRO-
MOTE-Paediatrics trial and not at the time when neurocogni-
tive testing was performed. Therefore, definite associations
between neurocognitive outcome and viral load/immune status
cannot be assessed using our findings. Of the 163 children
who completed the PROMOTE-Paediatrics trial, we were only
able to analyse data for 105 children. These 105 children may
represent a group that has slower disease progression and
better neurocognitive outcomes than those who were not
Table 3. Frequency of mild neurocognitive impairment among
the participantsa
Variable Total
Subtype
A(N = 78)
Subtype
D (N = 27) p
Overall cognition 6 (5.7) 5 (6.4) 1 (3.7) 1.00b
Attention 14 (13.3) 12 (15.4) 2 (7.4) 0.51b
Working memory 13 (12.4) 10 (12.8) 3 (11.1) 1.00b
Visual-spatial
processing
7 (6.7) 5 (6.4) 2 (7.4) 1.00b
Learning 18 (17.1) 12 (15.4) 6 (22.2) 0.55b
Reasoning 9 (8.6) 8 (10.3) 1 (3.7) 0.44b
Any impairment 35 (33.3) 26 (33.3) 9 (33.3) 1.00
Figures are n (%).
aMild neurocognitive impairment refers to a z score of ≤1.
bFisher’s exact test.
Table 4. Association between neurocognitive outcome and socio-demographic variables
CD4 count Viral load Sexa Years in school WAZ HAZ HOME SES score
Overall cognition 0.08 0.08 0.03 0.50*** 0.23* 0.37*** 0.34*** 0.22*
Attention 0.003 0.11 0.13 0.32*** 0.19* 0.47*** 0.20* 0.13
Motor skills 0.14 0.01 4.53*** 0.31** 0.34*** 0.42*** 0.20* 0.19
Working memory 0.06 0.15 0.23 0.36*** 0.33*** 0.38*** 0.20* 0.18
Visual-spatial processing 0.09 0.05 0.41** 0.45*** 0.30** 0.44*** 0.39*** 0.33***
Learning 0.04 0.06 0.48 0.41*** 0.02 0.17 0.24* 0.09
Reasoning 0.18 0.01 0.08 0.44*** 0.23* 0.33*** 0.32*** 0.20*
All values are correlation coefficients unless otherwise stated.
aMean difference in test scores between males and females.
*p < 0.05; **p < 0.01; ***p < 0.001.
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located during follow-up, which may affect our results. Finally,
the sample size was not adequate to detect differences
between the groups that corresponded to effect sizes below
d = 0.63. While there is no consensus on the cutoff for clinical
significance, differences between groups exceeding 1/3 or 1/2
of the standard deviation (effect sizes exceeding 0.33 or 0.5)
are often deemed clinically significant [36,37]. In the present
study, only one of the effect sizes (0.42 for visual-spatial pro-
cessing) was in this range, but statistical significance was not
reached with the available sample size.
5 | CONCLUSIONS
We observed no differences in neurocognitive outcomes
between subtype A and D in children who were on ART. A
probable explanation for this observation could be optimal
viral load suppression by ART in the majority. This study pro-
vides additional support for the current WHO guidelines to
treat all HIV-infected children.
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